Clinicians Can Help Their Patients Control Postprandial Hyperglycemia as a Means of Reducing Cardiovascular Risk

Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes. Having diabetes is now recognized as conferring the same risk for cardiovascular disease as hyperlipidemia, hypertension, and smoking. HbA1c levels are the primary indicator of diabetes control and overall glycemic exposure. And recent research has pointed to postprandial hyperglycemia as conferring a greater risk of cardiovascular disease than elevated fasting plasma glucose levels. Unfortunately, clinicians sometimes forget that elevated HbA1c levels can arise from both fasting hyperglycemia and postprandial hyperglycemia. This is particularly important to remember when treating patients whose HbA1c levels may be higher than the desired target while fasting plasma glucose test results are within reference range. This article reviews the evidence supporting the view that postprandial hyperglycemia is a risk factor for cardiovascular disease and therefore should be controlled. Case studies are presented to aid clinicians in helping patients learn how to measure and control their postprandial glucose levels.

[1]  Bruce W Bode,et al.  Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. , 2005, Diabetes care.

[2]  A. Denniston,et al.  More on porphyrias , 2005, The Lancet.

[3]  Kathryn Tan,et al.  Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004)* , 2005, Current medical research and opinion.

[4]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[5]  H. Woerle,et al.  Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. , 2004, Archives of internal medicine.

[6]  R. Marfella,et al.  Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus , 2004, Circulation.

[7]  S. Bowlin,et al.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. , 2004, Diabetes care.

[8]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[9]  Claude Colette,et al.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). , 2003, Diabetes care.

[10]  T. Erlinger,et al.  Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. , 2001, Diabetes care.

[11]  S. Schwartz,et al.  Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. , 2000, Diabetes care.

[12]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[13]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[14]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[15]  Beverley Balkau,et al.  High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.

[16]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.